Kadimastem Ltd (TLV: KDST)
Israel
· Delayed Price · Currency is ILS · Price in ILA
1,214.00
-1.00 (-0.08%)
Nov 14, 2024, 5:24 PM IDT
Kadimastem Company Description
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases.
Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes.
The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Kadimastem Ltd
Country | Israel |
Founded | 2008 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 12 |
CEO | Asaf Shiloni |
Contact Details
Address: Pinchas Sapir 7 Ness Ziona, 74140 Israel | |
Phone | 972 73 797 1600 |
Website | kadimastem.com |
Stock Details
Ticker Symbol | KDST |
Exchange | Tel Aviv Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | ILS |
ISIN Number | IL0011284614 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Ronen Twito CPA | Executive Chairman and President |
Uri Ben-Or | Chief Financial Officer |
Prof. Michel Revel M.D., Ph.D. | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board and Director |
Yossi Ben-Yossef | Honorary President and Strategic Consultant |
Olivier Samuel | Vice President of European Business Development and Director |